Zum Inhalt springen

Component changes under the MDR: what medical device manufacturers must consider with discontinuations

A misjudged component change can jeopardise the transitional status of a legacy device. What counts as a significant change, what the notified body needs to know and which tests may follow.

Modern operating room with operating table, ceiling lights and medical equipmentIndustries

Foto: Marcel Scholte / Unsplash

In brief: A discontinued component forces medical device manufacturers to change the product – and every change must be assessed from a regulatory perspective. Under the MDR, a misjudged component change can jeopardise the transitional status of a legacy device or trigger a review by the notified body. Recognising discontinuations early makes it possible to decide whether to stock up, switch or bundle changes.

Why obsolescence is delicate in medical technology

Medical devices are often on the market for ten years and longer and in use even longer. The electronics inside follow the short cycles of the semiconductor industry. In addition, there are special features:

  • Regulated changes: every change to the product must be assessed and documented, some require the approval of the notified body.
  • Legacy devices in transition: many products are still placed on the market under a certification according to the old directives. This status depends on conditions.
  • Service over the lifetime: devices must remain maintainable and repairable over the lifetime defined by the manufacturer.
  • Testing effort: electrical safety, EMC, software and risk management can be affected by a component change.

Legacy devices: no significant changes

Under Article 120 of the MDR, devices with a valid certificate under the old directives may continue to be placed on the market for a transitional period. Regulation (EU) 2023/607 extended these deadlines, depending on the risk class until the end of 2027 or the end of 2028, under certain conditions.

One of these conditions: the device must not undergo significant changes in design or intended purpose. This is exactly where obsolescence becomes a risk. If a component has to be replaced, it must be checked whether the change is significant. If it is, the device can no longer be supplied under the transitional status.

What counts as significant is explained in the guidance document MDCG 2020-3 (revised in 2023). It contains decision trees, among others for changes to design, software and materials. Some changes – such as a new supplier for a component with an unchanged specification – can be considered non-significant according to the guidance, as long as they do not adversely affect the benefit-risk ratio. What matters is a traceable, documented assessment in each individual case.

For legacy devices in the MDR transition, plan stockpiling so that, if possible, no design change is needed until MDR certification.

MDR-certified devices: changes to the notified body

Even for devices with an MDR certificate, a component change is not just an internal matter. Changes to the approved design that could affect conformity must be reported to the notified body. It reviews and, if necessary, approves the change. This takes time, which is often short in the event of a discontinuation.

What a component change can trigger technically

AreaPossible consequences
Risk managementupdate of the risk analysis according to ISO 14971
Electrical safetyrenewed tests according to IEC 60601-1, depending on the component
EMCrenewed tests according to IEC 60601-1-2, for example for processors, switching regulators or radio modules
Softwarechanges and verification according to IEC 62304 if a device affects the software; discontinued operating systems and software modules (SOUP) are also obsolescence
Biocompatibilityassessment according to ISO 10993 if materials with patient contact change
Technical documentationadaptation of documentation, labelling and, if necessary, instructions for use

Spare parts over the lifetime

Manufacturers must support their devices over the defined lifetime. Article 23 of the MDR regulates parts that specifically replace defective or worn parts of a medical device: they must not impair the safety and performance of the device. For obsolescence management this means: the spare parts demand over the entire lifetime belongs in every demand calculation – not just series production.

Strategies that have proven themselves

StrategyHow it helps
Assess obsolescence already in developmentcomponents with long availability and a second source reduce later changes
Monitor bills of materials continuouslydiscontinuations become visible early, the regulatory assessment can start in time
Life of need buy for legacy devicesavoids changes that jeopardise the transitional status
Bundle changesseveral discontinuations in one change, for example together with MDR certification
Prove equivalence properlydocument form, fit and function of the replacement component as the basis for the significance assessment
Talk to the notified body earlyclarifies expectations and shortens the review

How to calculate the quantity for a final order is shown in the article Calculating a last-time buy. What belongs in an obsolescence management plan can be read in the article Obsolescence management plan according to IEC 62402.

Typical mistakes

  • A component change is implemented before the regulatory assessment is completed
  • For legacy devices, it is not checked whether the change jeopardises the transitional status
  • Discontinued software components and operating systems are not monitored
  • Spare parts demand over the lifetime is missing from the demand calculation
  • The notified body is only informed when time is already short

Frequently asked questions

Is every component change a significant change?

No. Whether a change is significant depends on what changes in design, performance and risk. The guidance document MDCG 2020-3 helps with the classification. The assessment must be made in each individual case and documented.

Can a legacy device lose its transitional status through a discontinuation?

Yes, if replacing the component means a significant change in design or intended purpose. It is therefore worth stocking up early for legacy devices and bundling design changes with MDR certification.

Does the notified body have to be informed of every component change?

For MDR-certified devices, changes that could affect conformity must be reported. Which ones these are should be clearly regulated in the quality management system – ideally agreed with the notified body.

An overview of the basics is given in the article What is obsolescence management?.

Regulations: Regulation (EU) 2017/745 (MDR), in particular Art. 23 and Art. 120; Regulation (EU) 2023/607 (extension of the transition periods); MDCG 2020-3 Rev.1 (significant changes); ISO 14971, IEC 60601-1, IEC 60601-1-2, IEC 62304, ISO 10993; IEC 62402:2019. This article does not replace regulatory advice in the individual case.

Dominik Göttler

About the author

Dominik Göttler

Obsolescence manager · certified according to IEC 62402

Engineer and specialised obsolescence manager with more than 100 discontinuation cases handled in aerospace, medical technology, defence and transport. Publications in Productronic, Markt&Technik and all-electronics.

More about the author

Discontinuation in a medical device?

In 15 minutes we look together at how you can plan component changes without jeopardising approval and deliverability. Free of charge and without obligation.

Book a free call